DOT1L promotes phenotypic transition of vascular smooth muscle cells following vascular injury in diabetes through activation of the FGFR4/PI3K/AKT/Jag/Notch signaling pathway
Cellular Signalling · 2026-02 · 138 · 112223
DOI: 10.1016/j.cellsig.2025.112223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-02. Verfasst von Jing Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China;…. Hauptthemen laut MEDLINE: Muscle, Smooth, Vascular, Myocytes, Smooth Muscle, Diabetes Mellitus, Experimental, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hubei Province Natural Science Foundation, Hebei Provincial Key Research Projects.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Vascular smooth muscle cell (VSMC) phenotypic transition contributes to restenosis, impacting the long-term efficacy of percutaneous coronary intervention in diabetic patients. While DOT1L is known to regulate atherosclerosis, its role in diabetic VSMC phenotypic modulation remains unclear. Using insulin-stimulated rat thoracic aorta VSMCs and a diabetic rat carotid artery balloon injury model, we investigated VSMC proliferation, migration, and collagen synthesis. Histological and molecular analyses were performed to assess vascular remodeling and protein expression. Our findings revealed that 100 nmol/L insulin stimulation for 24 h or 28 days post-injury significantly increased DOT1L and H3K79me1 expression, correlating with VSMC phenotypic changes. DOT1L overexpression upregulated synthetic phenotype proteins in VSMCs and carotid arteries, with a 4.07-fold increase in H3K79me1 at the FGFR4 promoter region, activating the PI3K/AKT/Jag1/Notch1 pathway. These results demonstrate that DOT1L promotes intimal hyperplasia in diabetic vascular injury by mediating VSMC phenotypic switching through H3K79me1-mediated FGFR4 activation and subsequent PI3K/AKT/Jag1/Notch1 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China; Hubei Key Laboratory of Ischemic Cardiovascular Disease, Yichang, Chi…
- Hubei Key Laboratory of Ischemic Cardiovascular Disease, Yichang, China; Hubei Provincial Clinical Research Center for Ischemic Cardiovascular Disease, Yichang, China; Department of Cardiology, The First College of Clin…
Förderung
- National Natural Science Foundation of China
- Hubei Province Natural Science Foundation
- Hebei Provincial Key Research Projects
- Health Commission of Hubei Province
Zitieren
APA
Zhang, J., Wu, D., Cheng, C., Yang, Z., Chen, Z., Liu, L., Li, W., Wang, W., Huang, C., & Yang, J. (2026). DOT1L promotes phenotypic transition of vascular smooth muscle cells following vascular injury in diabetes through activation of the FGFR4/PI3K/AKT/Jag/Notch signaling pathway. Cellular Signalling, 138, 112223. https://doi.org/10.1016/j.cellsig.2025.112223
Vancouver
Zhang J, Wu D, Cheng C, Yang Z, Chen Z, Liu L, et al. DOT1L promotes phenotypic transition of vascular smooth muscle cells following vascular injury in diabetes through activation of the FGFR4/PI3K/AKT/Jag/Notch signaling pathway. Cellular Signalling. 2026;138:112223. doi:10.1016/j.cellsig.2025.112223
BibTeX
@article{Zhang2026,
author = {Zhang, Jing and Wu, Di and Cheng, Chen and Yang, Zishu and Chen, Zihao and Liu, Li and Li, Wenqiang and Wang, Wei and Huang, Cuiyuan and Yang, Jian},
title = {DOT1L promotes phenotypic transition of vascular smooth muscle cells following vascular injury in diabetes through activation of the FGFR4/PI3K/AKT/Jag/Notch signaling pathway},
journal = {Cellular Signalling},
year = {2026},
volume = {138},
pages = {112223},
doi = {10.1016/j.cellsig.2025.112223}
}
EUVIMED